News
All →Publications
All →Estimation of background rates of adverse events of special interest in neonatal outcomes: preterm births,...
During pregnancy, women and infants are predisposed to specific infections due to various immunological and physiological changes. These infections can...
The global smart pharmacovigilance strategy
Trust in regulated medical products (medicines, vaccines and other health products) to protect health, is mostly based on a number of principles: the...
World Local Production Forum on enhancing access to medicines and other health technologies: report of...
This report provides an overview of the third WLPF, held from April 7 to 9, 2024, in Abu Dhabi, United Arab Emirates. Organized by the WHO Local Production...
WHO Drug Information - Volume 39, No. 3
The Third issue of volume 39 for 2025 includes:Consultation Documents: Cefiderocol sulfate tosilate (cefiderocoli sulfas tosilatum) Cefiderocol powder...
Related documents
Greener Pharmaceuticals' Regulatory Highway
An effective regulatory system plays a critical role in ensuring the quality of health products, spanning from their development in the laboratory to their...
Newsletters
All →WHO pharmaceuticals newsletter - No. 2, 2025
The WHO pharmaceuticals newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities...
Report of the 48th meeting of the WHO Global Advisory Committee on Vaccine Safety, 15–16 May 2025
The Global Advisory Committee on Vaccine Safety (GACVS) was established in 1999, and the Advisory Committee on Safety of Medicinal Products (ACSoMP)...